Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report

Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report

Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by heterogenous lesions infiltrated with CD1a+/CD207+ cells. Although LCH has a relatively good prognosis, the prognosis for patients with LCH refractory to standard chemotherapy is poor. Neurodegenerative LCH (ND-LCH)...

Full description

Bibliographic Details
Main Authors: Young Kwon Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im, Pyeong Hwa Kim, Ah Young Jung, Kyung-Nam Koh
Format: Article
Language:English
Published: The Korean Society of Pediatric Hematology-Oncology 2022-10-01
Series:Clinical Pediatric Hematology-Oncology
Subjects:
lch
langerhans cell histiocytosis
vemurafenib
Online Access:https://doi.org/10.15264/cpho.2022.29.2.97

Similar Items

Similar Items